Proliferative vitreoretinopathy refers to retinal detachment behind the rear surface of the retina is a common eye disease that occurs due to the failure of the reset operation. Its pathogenesis is the retinal surface and the vitreous body behind extensive fiber proliferation film shrinkage caused by pulling retinal detachment. Fibrous proliferation membrane is mainly composed of pigment epithelial cells, glial cells, fibroblasts, fibroblasts, and macrophages. Pigment epithelial cells play an essential role in the occurrence and development of proliferative vitreoretinopathy. It is not only the primary cell for the formation and contraction of proliferative membranes, but also can produce stimulating factors. That attracts fibrocytes and fibroblasts to participate in the proliferation of membrane Formation.
The global Proliferative Vitreoretinopathy market is fueling with a propelling CAGR in the forecast period from 2020-2027. The rising old age population, failure in the surgery of rhegmatogenous retinal detachment (RRD). Other causes of illness such as excessive condensation, coagulation, trauma, high retinal tear, long-term retinal detachment, multiple intraocular surgeries, ocular trauma, and endophthalmitis psychosis are drivers of the market of Proliferative Vitreoretinopathy.
The formation of PVR involves a variety of cytokines, including platelet-derived growth factor (PDGF), blood vessels Endothelial growth factor, hepatocyte growth factor, transforming growth factor, epidermal growth factor, tumor necrosis factor, connective tissue growth factor, etc. The common symptoms of Proliferative Vitreoretinopathy are it causes a degree of vision loss, or visual field loss may occur. Thus, B-mode ultrasound and fundus fluorescein angiography can confirm the diagnosis of proliferative vitreoretinopathy.
Moreover, B-mode ultrasound done to produces a cross-sectional view of the eye and the orbit. When eye media is hazy due to cataract or any corneal opacity, then it is commonly used to see inside the eye.
Whereas, fundus fluorescein angiography (FFA) is a technique that uses the fluorescent light emitted by the intravenous injection of fluorescein to circulate the blood in the eye, and uses a camera equipped with a unique filter combination to record the dynamic changes of the fundus honestly. It breaks through the previous method of static observation of the fundus with ophthalmoscopes and other instruments. It has become one of the critical inspection methods for studying eye tissue anatomy, physiopathology, diagnosis and differential diagnosis, treatment, and prognosis.
Proliferative Vitreoretinopathy caused by retinal detachment pulling, rhegmatogenous retinal detachment is postoperative complications, one which majorly occurs in the old age. The cataract or haziness when it occurs inside the eyes and also, eyes with huge retinal holes have a significantly increased chance of PVR.
The advancement in technology in the healthcare industry has improved the surgery of PVR. Therefore, the primary treatment for PVR is surgical treatment, drug therapy, and FFD. Also, injecting slowly dissolving glucocorticoids into the vitreous can provide a long-acting therapeutic dose without systemic side effects.
Based on drug type, the global Proliferative Vitreoretinopathy market distributed into PRM-167, XOMA-089, Others. The XOMA-089 has dominated the largest market of the global Proliferative Vitreoretinopathy market. Intravitreal injection of XOMA 089 reduced the clinical stage and severity of PVR, including the severity of retinal detachment and formation of the intraocular membrane in both dose and time-dependent manner.
Moreover, a single injection of XOMA 089 is as efficient in inhibiting PVR as a weekly injection of XOMA 089 at the same dose level. The XOMA 089-mediated changes within retinal compartments characterized by decreased fibrosis, degeneration, and detachment. Final concentrations of XOMA 089 in rabbit vitreous humor showed sustained levels of exposure, and the peak concentrations of XOMA 089 in peripheral blood delayed and significantly lower than those of eyes.
Based on end-use, the global Proliferative Vitreoretinopathy market distributed into Hospitals, Clinics, Ambulatory Surgical Centers, Others. The hospital’s segment holds the largest market share in the global Proliferative Vitreoretinopathy market. The hospitals have the technologies, equipment, and other methods for the treatment of the Proliferative Vitreoretinopathy. Drugs such as XOMA 089 and PRM-167 majorly used in the hospitals for the treatment proliferative vitreoretinopathy. Therefore, hospitals have dominated the market share for the global proliferative vitreoretinopathy market and will continue to maintain its share in the future as well.
Based on geography, the global Proliferative Vitreoretinopathy market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America will be expecting to witness the highest growth during the forecast period from 2020-2027. North America captures the largest share in the proliferative vitreoretinopathy market. The robust healthcare facilities, continuous investment in research and development, advance technology, favorable government policies, and emerging healthcare infrastructure are booming the proliferative vitreoretinopathy market in North America.
Companies such as Novartis AG, Promedior, Inc., RXi Pharmaceuticals Corp., Allergan plc, Regeneron Pharmaceuticals, Inc., Genentech, Inc., among others, are key players in the global Proliferative Vitreoretinopathy market.
By Drug Type